CancerNetwork Members: Login | Register
Become a fan on  Facebook  Add us on  Google Plus Follow us on  Twitter Join us on LinkedIn Sign up for our Newsletters Subscribe to our RSS Feed

 

CancerNetwork SearchMedica Medline Drugs

Powered by SearchMedica

 
PUBLICATIONS
NEWS
PODCASTS
TOPICS
BLOGS
NURSES
PATIENTS
JOBS
CONFERENCES
CME
SUPPLEMENTS
 

Home » NEWS

Oncology NEWS International. Vol. 15 No. 9
Pages: 1  2  
Next
 

Postchemo Disappearance of Liver Mets Doesn't Mean Cure

September 1, 2006

ATLANTA—Chemotherapy may render some liver metastases of colorectal cancer no longer visible by preoperative CT and ultrasound imaging (see also article on page 21), but viable cancer cells are still present in about four in five of these sites. This was the key finding of a study presented at the 42nd Annual Meeting of the American Society of Clinical Oncology (abstract 3501).

"Most patients with colorectal liver metastases receive systemic chemotherapy if the metastases are unresectable or before surgery, and the tumor response to chemotherapy is assessed on imaging with CT scans," said Bernard Nordlinger, MD, of the Hpital Ambroise Par, Boulogne, France. "Complete response on imaging is defined as the disappearance of target lesions and is considered the best indicator of the efficacy of chemotherapy, but the significance of complete response of liver metastases on imaging after chemotherapy is not certain."

Dr. Nordlinger and his colleagues conducted a study to assess the correlation between complete response on imaging and complete pathologic response, and to determine if liver metastases that disappear on imaging after chemotherapy can be considered as cured. Searching the records of 586 consecutive patients treated for liver metastases of colorectal cancer at their institution between 1998 and 2004, the investigators identified 38 who met study inclusion criteria (presence of up to 10 liver metastases before treatment, and disappearance on CT and ultrasound imaging of at least one liver metastasis after chemotherapy).

The patients underwent triple-phase helical CT scanning combined with ultrasound before starting chemotherapy and after every three to four cycles. Three criteria were required to document disappearance of liver metastases: no more visible lesion at the initial site, no ring enhancement, and no calcification.

At the time of surgery, surgeons carefully inspected and palpated the liver, and performed intraoperative ultrasound at each of the initial sites of liver metastases. The preoperative finding of disappearance was confirmed if no lesion and no calcification were identified. For liver metastases that had been judged as initially resectable before their disappearance, surgeons resected the site. For initially unresectable bilobar metastases that became resectable after disappearance of some metastases, surgeons re-sected visible metastases and left the sites that had disappeared in place.

All resected specimens were examined pathologically, with special attention to the sites of metastases. After surgery, patients continued the chemotherapy regimen given preoperatively and underwent clinical, CT, and ultrasound examination every 4 months for 2 years and then every 6 months thereafter, he said.

Study Findings

Preoperative chemotherapy was associated with the disappearance on CT and ultrasound images of 66 liver metastases in the 38 patients. The maximal initial diameter of the metastases was 20 mm, on average, and all of the metastases that disappeared measured less than 45 mm.

Pages: 1  2  
Next
 

Join the Conversation

Want to join the conversation? If you're a healthcare professional, we'd like to hear your comments. Just sign in or register today to become part of our growing, online community.






 
TOPIC INDEX

Cancer Types

 
  • Breast
  • Breast (HER2+)
  • Breast (Triple-Negative)
  • CML
  • Colorectal
  • Gastrointestinal
  • GIST
  • Genitourinary
  • Gynecologic
  • Head & Neck
  • Hematology
  • Kidney (Renal Cell)
  • Leukemia
  • Lung
  • Lymphoma
  • Melanoma
  • Multiple Myeloma
  • Ovarian
  • Prostate
  • Sarcoma

Supportive Care

More Topics

  • Bone Metastases
  • End-of-Life Care
  • Palliative Care
  • Ethics in Oncology
  • Practice Management
  • Practice & Policy


All Topics 


 
FROM PHYSICIANS PRACTICE
Key Differences between FQHCs and RHCs
Chastity Werner, RHIT, June 13, 2013
FQHCs and RHCs take up a unique niche among physician practices. And that affects compensation and billing.
Improving Care Coordination in Your Practice
Susanne Madden,  June 12, 2013
Practices are feverishly working to control the rising costs of healthcare - effective care coordination can help.
Refunding Overpayments: Two Options for Medical Practices
Ericka L. Adler,  June 12, 2013
Medicare and Medicaid providers must return overpayments once identified. Here are two different refund approaches for practices to consider when necessary.
Four Easy Ways to Boost Patient Time of Service Collections
Aubrey Westgate,  June 12, 2013
Simple ways your medical practice staff can increase the likelihood patients will pay when presenting for appointments.
iPad Alternatives for Mobile Physicians
Marisa Torrieri, June 11, 2013
As more physicians are seeing the merits of media tablets, the market is expanding, too.
 

 

 
MOST POPULAR
  • Most Popular
  • Most Emailed
  • Most Recent
  • Dermatologic Adverse Events Associated With Targeted Therapies
  • Papillary Thyroid Carcinoma
  • Robotic-Assisted Radical Prostatectomy: Who Is Benefiting?
  • ASCO: Long-Term Tamoxifen Benefit for Breast Cancer Confirmed
  • Lower Back Pain in an Elderly Man With a History of Localized Prostate Cancer
  • Cannabis Linked to Decreased Bladder Cancer Risk
  • Breast Cancer Screening, Risk, and Options for High-Risk Women
  • Recurrent Epithelial Ovarian Cancer: An Update on Treatment
  • Rising PSA Level in a 46-Year-Old Man
  • ASCO: Long-Term Tamoxifen Benefit for Breast Cancer Confirmed
  • Bladder Cancer Recurrence High, Better Follow-Up Care Needed
  • ASCO: Post-Surgery Surveillance Found Safe in Seminoma
  • Fertility Preservation in Women With Breast Cancer: Challenges and Opportunities
  • Addressing Fertility Concerns in Women Diagnosed With Breast Cancer: Will Serial Reserve Screening Help?
  • Postmenopausal Hormone Receptor–Positive Advanced Breast Cancer
Click here to subscribe to our newsletter


CancerNetwork on Facebook


CancerNetwork | ConsultantLive | Diagnostic Imaging | Musculoskeletal Network | OBGYN.net | PediatricsConsultantLive |
Physicians Practice | Psychiatric Times | SearchMedica | Medical Resources

© 1996 - 2013 UBM Medica LLC, a UBM company
Privacy Statement - Terms of Service - Advertising Information - Editorial Policy Statement - UBM Medica Network Privacy Policy